Stevia for Blood Sugar and Diabetes

The single most useful sentence anyone can say about stevia and blood sugar is this: it does not raise blood glucose, and it does not lower it either. Everything worth knowing follows from that. Stevia is not a drug for diabetes. It is a way of removing sugar from a food without removing the sweetness, and the entire measurable benefit lives in what it displaces.

That is a smaller claim than the marketing, and a much bigger one than the sceptics allow. Replacing a daily 350 ml sugar-sweetened soft drink with a stevia-sweetened one removes roughly 35 grams of rapidly absorbed sugar and about 140 kilocalories from the day. Over a year that is roughly 13 kilograms of sugar not consumed. No herb does anything that impressive by acting on a receptor.

Three Different Things Are Sold as "Stevia"
Why Steviol Glycosides Have No Glycaemic Effect
What the Randomized Trials Show
The Acute Meal Studies
The Beta-Cell Hypothesis
The Real Benefit Is Substitution
Practical Use When You Have Diabetes
What Stevia Does Not Do
How Much Is Within the Limit
Key Research Papers
Safety Note and Disclaimer
Connections

1. Three Different Things Are Sold as "Stevia"

Nothing on this page can be read correctly without separating them, because the evidence does not transfer between them.

Whole stevia leaf — dried or fresh leaves of Stevia rebaudiana. This is the form with centuries of Guaraní use. In the United States it is not an approved sweetener (the FDA maintains an import alert on leaf and crude extract for food use), and it is not authorised as a sweetener in the European Union either. It is legally sold in the US only as a dietary supplement or herbal tea, a different regulatory pathway. Essentially none of the glycaemic trials below used whole leaf.
Purified steviol glycosides — rebaudioside A, stevioside, and increasingly rebaudiosides D and M, refined to not less than 95% total glycosides. This is the approved sweetener: GRAS-notified in the US since 2008, authorised in the EU as additive E 960. The Acceptable Daily Intake set by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) is 4 mg per kg of body weight per day, expressed as steviol equivalents. This is what nearly every trial on this page tested.
Retail "stevia" tabletop products — the packets and spoonable tubs. By weight these are overwhelmingly a bulking agent — usually erythritol, sometimes dextrose or maltodextrin — carrying a trace of rebaudioside A. A rebaudioside is 200 to 400 times sweeter than sugar, so a teaspoon-equivalent of it is a few milligrams; something has to fill the spoon. The bulking agent is not stevia and does not behave like it.

Point 3 is where most people with diabetes actually get hurt, and section 7 deals with it directly.

2. Why Steviol Glycosides Have No Glycaemic Effect

Human digestive enzymes cannot cleave the beta-glucosidic linkages that hold the sugar units onto the steviol core, and the intact glycoside molecules are too large and too polar to cross the small-intestinal wall efficiently. They therefore pass the entire small intestine essentially untouched.

In the colon, bacteria — principally Bacteroides species — hydrolyse off the sugars, releasing free steviol. Steviol is small and lipophilic, is absorbed across the colonic wall, travels to the liver, is conjugated to steviol glucuronide, and is excreted in the urine. This route was mapped in human faecal-microflora work such as Metabolism of stevioside and rebaudioside A from Stevia rebaudiana extracts by human microflora (Journal of Agricultural and Food Chemistry, 2003) and confirmed in human pharmacokinetic studies.

Three consequences follow, and they are mechanistic facts rather than claims:

No absorbable carbohydrate reaches the bloodstream. The sugar units are released in the colon, in milligram quantities, past the point where glucose absorption occurs.
No insulin is released by the sweetener. There is no glucose rise to trigger it.
The colonic microbiota are a required intermediate step, which is why the microbiome question is a real one rather than an invented one. That is covered on the Microbiome and Safety page.

3. What the Randomized Trials Show (Evidence Tier: Clinical)

The controlled human evidence on steviol glycosides and glucose control is unusually consistent, and consistently negative — meaning no harm and no benefit to glycaemia from the sweetener itself.

Maki and colleagues (2008), Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus, Food and Chemical Toxicology. Adults with type 2 diabetes took 1,000 mg/day of rebaudioside A for 16 weeks. There was no significant difference from placebo in HbA1c, fasting glucose, fasting insulin, C-peptide or lipids. Note the dose — 1 gram a day is far above ordinary tabletop use.
Barriocanal and colleagues (2008), Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans, Regulatory Toxicology and Pharmacology. Three months of 250 mg steviosides three times daily in people with type 1 diabetes, type 2 diabetes and healthy normotensive controls. No significant change in glucose control — and, importantly for the blood pressure question, none in blood pressure either.
Nichol, Holle and An (2018), Glycemic impact of non-nutritive sweeteners: a systematic review and meta-analysis of randomized controlled trials, European Journal of Clinical Nutrition. Pooling the acute trials across sweetener types, the effect on blood glucose was not significantly different from zero.
Ajami and colleagues (2020), Effects of stevia on glycemic and lipid profile of type 2 diabetic patients: a randomized controlled trial, Avicenna Journal of Phytomedicine. A small trial in Iran reporting improvements in some glycaemic measures; single-centre, modest size, and it should be read alongside the larger negative trials rather than instead of them.

PubMed: rebaudioside A, type 2 diabetes, randomized trials

4. The Acute Meal Studies (Evidence Tier: Clinical, Small)

Acute studies ask a different question: what happens when stevia is consumed with or before a meal?

Anton and colleagues (2010), Effects of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels, Appetite. Participants who had a stevia preload before a meal had lower post-meal glucose and insulin than after a sucrose preload — and did not compensate by eating more later. This is a study about substituting for sugar. It does not show stevia doing anything on its own.
Tey and colleagues (2017), Effects of aspartame-, monk fruit-, stevia- and sucrose-sweetened beverages on postprandial glucose, insulin and energy intake, International Journal of Obesity. The three non-nutritive sweeteners behaved essentially identically to each other and differently from sucrose — again a substitution effect, not a stevia-specific one.
Stamataki and colleagues (2020), Stevia beverage consumption prior to lunch reduces appetite and total energy intake without affecting glycemia, The Journal of Nutrition. Note the second half of that title: appetite moved, glycaemia did not.

PubMed: stevia preload and postprandial glucose

5. The Beta-Cell Hypothesis — Interesting, Not Established (Evidence Tier: Preliminary)

There is a genuinely intriguing outlier in the literature. Gregersen and colleagues (2004), Antihyperglycemic effects of stevioside in type 2 diabetic subjects, Metabolism, gave 1 gram of stevioside with a test meal to twelve people with type 2 diabetes and reported roughly an 18% reduction in the incremental glucose area under the curve, with a higher insulinogenic index.

Take that seriously and take it in proportion. Twelve participants. A single dose. One gram of stevioside is perhaps forty to eighty times a typical daily tabletop intake, delivered as a drug rather than a sweetener. And it has not been consistently replicated — the larger, longer trials in section 3 measured HbA1c and fasting glucose and found nothing.

The mechanistic backing is laboratory work: isolated mouse islet and rodent studies suggesting stevioside and its aglycone steviol can enhance glucose-dependent insulin secretion and blunt glucagon, possibly through effects on ATP-sensitive potassium channels and on TRPM5 taste-receptor signalling in beta cells. Some rodent work also reports improved insulin sensitivity. None of this has been shown to occur in humans at intakes anyone actually consumes, and it is a long way from an isolated islet to a person's HbA1c.

PubMed: stevioside and pancreatic insulin secretion

6. The Real Benefit Is Substitution

If stevia does not act on glucose metabolism, why does it appear in almost every practical diabetes resource? Because sugar-sweetened beverages are one of the most tractable single targets in a diabetic diet, and sweetness is the hardest thing to give up.

McGlynn and colleagues (2022), Association of low- and no-calorie sweetened beverages as a replacement for sugar-sweetened beverages with body weight and cardiometabolic risk, JAMA Network Open, pooled the randomized substitution trials and found that replacing sugar-sweetened drinks with low- and no-calorie sweetened drinks produced modest improvements in body weight and in several cardiometabolic markers — comparable to replacing them with water in most respects.

The word replacement is doing all the work. Stevia added on top of an unchanged diet does nothing at all. Stevia standing where sugar used to stand removes the sugar.

7. Practical Use When You Have Diabetes

Read the ingredient list, not the front of the packet. This matters more than any other advice here.

Dextrose-bulked packets raise blood glucose. Dextrose is glucose. A packet is typically about 1 gram of it — small, but it is not zero, and it is not what the label implies. In the US, products under 5 kcal per serving may be labelled "zero calorie". Six packets in a mug of coffee is 6 grams of glucose that nobody counted.
Maltodextrin is worse per gram than table sugar on the glycaemic index, and it turns up in some spoonable blends.
Erythritol-bulked products do not raise glucose meaningfully — erythritol is absorbed in the small intestine and excreted essentially unchanged in urine. It has its own separate question, discussed on the Microbiome and Safety page.
Pure glycoside drops and liquid concentrates avoid the bulking-agent question entirely, at the cost of being awkward to bake with.
Baking is a real limitation. Sugar provides bulk, browning, moisture retention and structure. Removing 200 grams of sugar from a cake and adding 60 milligrams of rebaudioside A removes 199.94 grams of physical substance. This is why baking blends contain so much filler, and why "stevia-sweetened" baked goods often carry more carbohydrate than the label's headline suggests.

8. What Stevia Does Not Do

Stated plainly, because these claims circulate:

It does not lower HbA1c. The 16-week and 3-month trials measured this specifically and found no effect.
It does not reverse insulin resistance. No human trial supports this.
It does not replace medication. Nobody should reduce metformin, a GLP-1 agonist, or insulin because they switched sweeteners. See Metformin and GLP-1 Receptor Agonists.
It does not "heal the pancreas." The islet studies are in vitro and in rodents.
Whole-leaf stevia has no glycaemic trial evidence at all. Traditional use is history, not data.

9. How Much Is Within the Limit

The JECFA Acceptable Daily Intake is 4 mg/kg body weight/day as steviol equivalents, which the European Food Safety Authority adopted in its 2010 opinion on E 960. Steviol equivalents are not the same as product weight — a conversion factor of roughly 0.33 applies to rebaudioside A and about 0.40 to stevioside.

For a 70 kg adult that is 280 mg/day of steviol equivalents, corresponding very roughly to 850 mg of rebaudioside A. Because a tabletop packet contains only a few milligrams of glycoside, ordinary use sits far below the limit. Intake surveys in Europe and North America have generally found even high consumers below the ADI, with the exception of some modelling for young children whose intake is high relative to body weight. The ADI is a lifetime-average figure with a hundredfold safety margin built in, not a cliff edge.

10. Key Research Papers

Every reference below is given as a PubMed search link rather than a direct record number, so that you resolve the paper yourself from its stated title, journal and year.

Maki KC et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology, 2008. — Find on PubMed
Barriocanal LA et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. Regulatory Toxicology and Pharmacology, 2008. — Find on PubMed
Gregersen S et al. Antihyperglycemic effects of stevioside in type 2 diabetic subjects. Metabolism, 2004. — Find on PubMed
Anton SD et al. Effects of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels. Appetite, 2010. — Find on PubMed
Nichol AD, Holle MJ, An R. Glycemic impact of non-nutritive sweeteners: a systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Nutrition, 2018. — Find on PubMed
Tey SL et al. Effects of aspartame-, monk fruit-, stevia- and sucrose-sweetened beverages on postprandial glucose, insulin and energy intake. International Journal of Obesity, 2017. — Find on PubMed
Stamataki NS et al. Stevia beverage consumption prior to lunch reduces appetite and total energy intake without affecting glycemia. The Journal of Nutrition, 2020. — Find on PubMed
McGlynn ND et al. Association of low- and no-calorie sweetened beverages as a replacement for sugar-sweetened beverages with body weight and cardiometabolic risk. JAMA Network Open, 2022. — Find on PubMed
Gardana C et al. Metabolism of stevioside and rebaudioside A from Stevia rebaudiana extracts by human microflora. Journal of Agricultural and Food Chemistry, 2003. — Find on PubMed
Ajami M et al. Effects of stevia on glycemic and lipid profile of type 2 diabetic patients: a randomized controlled trial. Avicenna Journal of Phytomedicine, 2020. — Find on PubMed
Samuel P et al. Stevia leaf to stevia sweetener: exploring its science, benefits, and future potential. The Journal of Nutrition, 2018. — Find on PubMed
Purkayastha S, Kwok D. Metabolic fate in adult and pediatric population of steviol glycosides produced from stevia leaf and bioconversion. Regulatory Toxicology and Pharmacology, 2020. — Find on PubMed

11. Safety Note and Disclaimer

Purified steviol glycosides have a large toxicological file behind them and are considered safe within the ADI by JECFA, the FDA and EFSA. That statement covers the purified glycoside only — not whole leaf, and not whatever bulking agent fills the packet.

If you take glucose-lowering medication, changing sweeteners will not change your dose requirement, but changing the total carbohydrate of your diet might. Monitor as usual and discuss any substantial dietary change with the clinician managing your diabetes. Nothing on this page is medical advice, a diagnosis, or a recommendation to alter prescribed treatment. This site is an educational resource, not a treatment service.

Connections

Back to Table of Contents